Antiangiogenic steroids in human cancer therapy

Evidence-based Complementary and Alternative Medicine

Volumn 2, Issue 1, 2005, Pages 49-57

  Pietras, Richard J ^a   Weinberg, Olga K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Malignancy; Squalamine; Tumor associated angiogenesis; Vascular endothelial growth factor (VEGF)

Indexed keywords

ACTIN; ANGIOGENESIS INHIBITOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; GEMCITABINE; GENISTEIN; LIVER ENZYME; NAVELBINE; ORPHAN DRUG; PACLITAXEL; SODIUM PROTON EXCHANGE PROTEIN; SPERMIDINE; SQUALAMINE; STEROID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACTIN POLYMERIZATION; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIANGIOGENIC ACTIVITY; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER THERAPY; CELL ADHESION; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG BINDING; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOTHELIUM CELL; FATIGUE; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MEMBRANE TRANSPORT; MYALGIA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN POLYMERIZATION; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR VASCULARIZATION;

EID: 25844520830     PISSN: 1741427X     EISSN: None     Source Type: Journal    
DOI: 10.1093/ecam/neh066     Document Type: Review

References (55)

1. Parkin DM. Global cancer statistics in the year. Lancet Oncol 2001;2:596.
2. Reddy L, Odhav B, Bhoola KD. Natural products for cancer prevention: a global perspective. Pharmacol Therapeut 2003;99:1-13.
3. Alvarez AA, Krigman HR, Whitaker RS, Dodge RK, Rodriguez GC. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 1999;5:587-91.
4. Ferrara N, Winer, J, Burton T, et al. Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese Hanster Ovary cells. J Clin Invest 1993;91:160-70.
5. Folkman J, Haudenschild C. Angiogenesis in vitro. Nature 1980;288:551-6.
6. Folkman J, Ingber D. Inhibition of angiogenesis. Sem Cancer Biol 1992;3:89-96.
7. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-4.
8. Keck P, Hauser S, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;240:1309-12.
9. Leung D, Cachianes G, Kuang WJ, Goeddel D, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;240:1306-9.
10. Rousseau S, Houle F, Landry J, Huot J. P38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 1997;15:2169-77.
11. Rousseau S, Houle F, Korarides H, et al. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem 2000;275:10661-72.
12. Soker S, Fidder H, Neufeld G, Klagsbrun M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGP165 via its exon 7-encoded domain. J Biol Chem 1996;271:5761-7.
13. Paley PJ, Staskus KA, Gebhard K, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997; 80:98-106.
14. Yamamoto S, Konishi I, Mandai M, et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997;76:1221-7.
15. Li D, Williams J, Pietras R. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Oncogene 2002;21:2805-14.
16. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523-30.
17. Gilmour L, Macleod K, McCaig A, et al. Neuregulin expression, function and signaling in human ovarian cancer cells. Clin Cancer Res 2002;8:3933-12.
18. Hellstrom I, Goodman G, Pullman J, Yang Y, Hellstrom KE. Overexpression of HER-2 in ovarian carcinomas. Cancer Res 2001;61:2420-3.
19. Slamon DJ, Clark GM, Wong SJ, Levin WJ, Ulrich A, McGuire WJ. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
20. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
21. Wong YF, Cheung TH, Lam SK, et al. Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer. Gynecol Obstet Invest 1995;40:209-12.
22. Teicher BA, Williams JI, Takeuchi H, Ara G, Herbst R, Buxton D. Potential of the aminosterol, squalamine in combination therapy in the rat 13762 mammary carcinoma and the murine Lewis Lung Carcinoma. Anticancer Res 1998;18:2567-74.
23. Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983;221:719-25.
24. Sakamoto N, Tanaka NG, Tohgo A, Osada Y, Ogawa H. Inhibitory effects of heparin plus cortisone acetate on endothelial cell growth both in cultures and in tumor masses. J Natl Cancer Inst 1987;78:581-5.
25. Jakobsen A, Frederiksen PL, Moller KA, et al. Medroxyprogesterone acetate and prednisone in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol 1986;22:1067-72.
26. Mooberry SL. Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Updates 2003;6:355-61.
27. Eckhardt, SG. Angiogenesis inhibitors as cancer therapy. Hospital Pract 1999;1:63-78.
28. Sills AK Jr, Williams JI, Tyler BM, et al. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res 1998;58:2784-92.
29. Moore KS, Wehrli S, Roder H, et al. Squalamine: an aminosterol antibiotic from the shark. Proc Natl Acad Sci USA 1993;90:1354-8.
30. Bruss K, editor. American Cancer Society Guide to Complementary and Alternative Cancer Methods. Atlanta, GA: American Cancer Society, 2000.
31. Williams JI. Squalamine - A New Angiostatic Steroid. In Teicher BA, editor: Antiangiogenic Agents. Totowa, NJ: Humana Press, 1999.
32. Akhter S, Nath SK, Tse CM, William J, Zasloff M, Donowitz M. Squalamine, a novel cationic steroid, specifically inhibits the brush-border Na+/H+ exchanger isoform NHE3. Am J Physiol 1999;276:C136-44.
33. Chen Q, William JI, Anderson M, Kinney WK, Zasloff M. The angiostatic sterol squalamine is a calmodulin chaperone. Clin Cancer Res 1999;5(Suppl):3768s.
34. Williams JI, Weitman S, Gonzalez CM, et al. Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies. Clin Cancer Res 2001;7:724-33.
35. Pietras RJ, Gorrin-Rivas M, Chen H-W. Squalamine blocks tumor-associated angiogenesis and growth of ovarian cancer. Int J Obstet Gynecol 2003;83(Suppl 3):59-60.
36. Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1995;129:895-8.
37. Soker S, Fidder H, Neufeld G, Klagsbrun M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 1996;271:5761-7.
38. Schiller JH, Bittner G. Potentiation of platinum antitumor effects ill human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization. Clin Cancer Res 1999;5:4287-94.
39. Mueller MD, Vigne JL, Minchenko A, Lebovic DI, Leitman DC, Taylor RN. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. Proc Natl Acad Sci USA 2000;97:10972-7.
40. Mauceri HJ, Hanna NN, Beckett MA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998;394:287-91.
41. Williams JI, Mangold G, Zasloff M, Von Hoff DD. Evaluation of the natural aminosterol squalamine as adjunctive chemotherapy in the MX-1 breast cancer xenograft model. Breast Cancer Res Treat 1997;46:723-33.
42. DeVita VT Jr, Hellman S, Rosenberg SA. Cancer: Principles & Practice of Oncology. New York, NY: Lippincott-Raven, 2000.
43. DiSaia P, Bloss J. Treatment of ovarian cancer: new strategies. Gynecol Oncol 2003;90(2 Suppl):S24-32.
44. Ozols RF. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Sem Oncol 1999;26:84-9.
45. Stiff, PJ. The challenge of treating advanced ovarian cancer. Cancer Mgmt 1997;2:1-5.
46. Lewis G, Figari I, Fendly B, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255-63.
47. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999;6:373-8.
48. Kinney WA, Xhang X, Williams JI, et al. The challenge of treating advanced ovarian cancer. Organic Lett 2000;2:2921-2.
49. Bhargava P, Marshall JL, Dahut W, et al. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers. Clin Cancer Res 2001;7:3912-9.
50. Hao D, Hammond LA, Eckhardt SG, et al. A phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor. Clin Cancer Res 2003;9:2465-71.
51. Herbst RS, Hammond LA, Carbone DP, et al. A Phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 2003;9:4108-15.
52. Davidson SA, Chap L, Pietras R, et al. A phase IIA trial of continuous 5-day infusions of MSI-1256F (squalamine lactate) plus carboplatin for therapy of persistant or recurrent advanced ovarian cancer. Proc Am Soc Clin Oncol 2002;9:2465-71.
53. D'Angelo G, Struman I, Martial J, Weiner R. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kd N-terminal fragment of prolactin. Proc Natl Acad Sci USA 1995;92:6374-8.
54. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10:2435-16.
55. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999;59:1347-55.